royalties | GenomeWeb

royalties

Life Technologies last week reported a 1 percent decrease in revenues for its Genetic Analysis unit and flat sales in its Applied Sciences unit in the third quarter, contributing to a 2 percent decline in overall company revenues year over year.

By Ben Butkus
Roche has initiated an arbitration hearing against Cepheid in response to Cepheid's decision to terminate its real-time PCR license with Roche, PCR Insider has learned.

Amid reporting its earnings for the third quarter of 2011, Cepheid said today that it is terminating its PCR license with Roche after determining that patents covered by the license are "not pertinent" to Cepheid's future business plans.

The company reported a 3 percent decrease in organic revenue for its Molecular Biology Systems division in the first quarter of 2011 due primarily to "difficult" year-over year comparisons for its PCR and molecular biology reagents businesses.

An institutional investor has suggested that the firm spin out or distribute a royalty asset tied to a Merck phase III drug.

A new licensing team at Life Technologies helped reduce the decline in 2009 PCR patent royalties to around $20 million instead of $30 million, and it appears that 2010 will see no deterioration at all.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.